PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company's PI segment provides information technology solutions.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
Phone+1-781-4879900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18,900
OptionableNot Optionable
PAREXEL International (NASDAQ:PRXL) Frequently Asked Questions
What is PAREXEL International's stock symbol?
PAREXEL International trades on the NASDAQ under the ticker symbol "PRXL."
Has PAREXEL International been receiving favorable news coverage?
News stories about PRXL stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. PAREXEL International earned a coverage optimism score of 1.1 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the stock's share price in the immediate future.
Who are PAREXEL International's key executives?
PAREXEL International's management team includes the folowing people:
- Josef H. von Rickenbach, Chairman of the Board, Chief Executive Officer
- Mark A. Goldberg M.D., President, Chief Operating Officer
- Simon Harford, Chief Financial Officer, Senior Vice President
- , Bio & Compensation -
- Xavier AB Flinois, President - PAREXEL Informatics
- Michelle Graham, Chief Human Resource Officer, Senior Vice President
- Sybrand Pretorius M.D., Senior Vice President, Chief Scientific Officer
- Douglas Alexander Batt, Senior Vice President, General Counsel, Secretary
- Roland Andersson Ph.d., Senior Vice President - Clinical Research Services
- Christian Dreger Ph.D., Senior Vice President - Parexel Access and Parexel Consulting
- , Bio & Compensation -
- David J. Godwin, Senior Vice President-Global Business
How do I buy shares of PAREXEL International?
Shares of PRXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PAREXEL International's stock price today?
One share of PRXL stock can currently be purchased for approximately $88.08.
What is PAREXEL International's official website?
How can I contact PAREXEL International?
PAREXEL International's mailing address is 195 West St, WALTHAM, MA 02451-1111, United States. The medical research company can be reached via phone at +1-781-4879900.
MarketBeat Community Rating for PAREXEL International (NASDAQ PRXL)
MarketBeat's community ratings are surveys of what our community members think about PAREXEL International and other stocks. Vote "Outperform" if you believe PRXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
